saracatinib
saracatinib is a pharmaceutical drug with 21 clinical trials. Historical success rate of 75.0%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
17
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
75.0%
15 of 20 finished
25.0%
5 ended early
0
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
Saracatinib and Alcohol Drinking
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
Clinical Trials (21)
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
Saracatinib and Alcohol Drinking
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
Saracatinib in Treating Patients With Prostate Cancer
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 21